REPL Replimune Group, Inc.
USHealthcareAs of 2026-08-24
Why REPL matters now
Replimune Group, Inc. (REPL) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.71 with -0.41% on the session and $1.24B in market capitalization; recent performance reads 1-month +116.81% and YTD +4.84%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-70.9M, and EPS of $-0.77. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -33.7%.
The latest indexable market news headline is "Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $14.00; recent insider activity includes Sarchi Christopher filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.46
P/S
0.00
EV/EBITDA
-2.55
DCF Value
$0.33
FCF Yield
-33.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-102.7%
ROA
-94.4%
ROIC
-113.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-70.9M | $-0.77 |
| Q2 2026 | $0.00 | $-83.1M | $-0.90 |
| Q1 2026 | $0.00 | $-86.7M | $-0.95 |
| Q4 2025 | $0.00 | $-74.1M | $-0.96 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$14.00
Target (Median)
$14.00
Target Range
$14.00 - $14.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.91
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.